Literature DB >> 8960057

Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin.

S L Smith1, J Fishwick, W G McLean, G Edwards, S A Ward.   

Abstract

The role of haem in the neurotoxicity of artemisinin derivatives has been studied in vitro by examining neurite outgrowth measured by image analysis and cellular metabolism of the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) measured spectrophotometrically in the neuroblastoma cell line NB2a, and by examining binding of radiolabelled dihydroartemisinin to NB2a cell and rat brain proteins. In the cases of artemether, dihydroartemisinin, and arteether, haemin (ferriprotoporphyrin IX) significantly increased the dose-related inhibition of neurite outgrowth from differentiating NB2a cells and significantly increased the dose-dependent inhibition of MTT metabolism. Inhibition of neurite outgrowth and metabolism of MTT in the presence or absence of haemin ranged from 72% to 93% and from 27% to 49% at a drug concentration of 300 nM. Haemin also significantly increased the dose-related binding of radiolabelled dihydroartemisinin to proteins from NB2a cells approximately twofold and to rat brain between three- and sixfold. Haemin did not enhance the neurotoxicity of desoxyarteether, a structural analogue of arteether with an ether linkage in the place of the endoperoxide bridge. It is suggested that haemin may catalyse the transformation of these derivatives via an interaction with the endoperoxide bridge of the artemisinin derivative to produce free radicals or electrophilic intermediates that are toxic to neuronal cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8960057     DOI: 10.1016/s0006-2952(96)00591-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin-type..

Authors:  G Schmuck; R K Haynes
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Safety assessment of peroxide antimalarials: clinical and chemical perspectives.

Authors:  B K Park; P M O'Neill; J L Maggs; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

3.  Effects of artemisinin in broiler chickens following chronic oral intake.

Authors:  Amir Ali Shahbazfar; Seyed Hossein Mardjanmehr; Hossein Ali Arab; Ali Rassouli; Mohammad Abdollahi
Journal:  Trop Anim Health Prod       Date:  2011-01-01       Impact factor: 1.559

4.  Immunoprecipitation of [(3)H]dihydroartemisinin translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-infected erythrocytes by using anti-TCTP antibodies.

Authors:  J Bhisutthibhan; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria.

Authors:  K T Batty; L T Thu; T M Davis; K F Ilett; T X Mai; N C Hung; N P Tien; S M Powell; H V Thien; T Q Binh; N V Kim
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

6.  Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria.

Authors:  T M Davis; H L Phuong; K F Ilett; N C Hung; K T Batty; V D Phuong; S M Powell; H V Thien; T Q Binh
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Effects of different concentrations of artemisinin and artemisinin-iron combination treatment on Madin Darby Canine Kidney (MDCK) cells.

Authors:  Amir Ali Shahbazfar; Payman Zare; Hemn Mohammadpour; Hossein Tayefi-Nasrabadi
Journal:  Interdiscip Toxicol       Date:  2012-03

8.  Exogenous Iron Increases Fasciocidal Activity and Hepatocellular Toxicity of the Synthetic Endoperoxides OZ78 and MT04.

Authors:  Karin Brecht; Carla Kirchhofer; Jamal Bouitbir; Francesca Trapani; Jennifer Keiser; Stephan Krähenbühl
Journal:  Int J Mol Sci       Date:  2019-10-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.